Wells Fargo & Company Cuts Myriad Genetics (NASDAQ:MYGN) Price Target to $6.00

Myriad Genetics (NASDAQ:MYGN) had its price objective decreased by equities researchers at Wells Fargo & Company from $6.50 to $6.00 in a report issued on Tuesday,Benzinga reports. The brokerage presently has an “equal weight” rating on the stock. Wells Fargo & Company‘s target price points to a potential upside of 28.34% from the company’s current price.

Several other equities analysts have also recently weighed in on the stock. UBS Group reaffirmed a “neutral” rating and issued a $6.00 price target on shares of Myriad Genetics in a research report on Tuesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Myriad Genetics in a research report on Monday, December 29th. Zacks Research cut Myriad Genetics from a “hold” rating to a “strong sell” rating in a research note on Monday, January 19th. TD Cowen reaffirmed a “hold” rating on shares of Myriad Genetics in a report on Tuesday, November 4th. Finally, Piper Sandler lowered their target price on shares of Myriad Genetics from $9.00 to $8.50 and set an “overweight” rating for the company in a report on Tuesday, November 11th. Four equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and three have given a Sell rating to the company’s stock. According to MarketBeat.com, Myriad Genetics presently has a consensus rating of “Hold” and a consensus target price of $9.17.

Myriad Genetics Trading Up 6.7%

Shares of MYGN stock traded up $0.30 on Tuesday, hitting $4.68. The company had a trading volume of 1,452,565 shares, compared to its average volume of 1,013,648. Myriad Genetics has a twelve month low of $3.76 and a twelve month high of $12.28. The company has a debt-to-equity ratio of 0.32, a quick ratio of 2.12 and a current ratio of 2.33. The firm has a market cap of $435.76 million, a P/E ratio of -1.07 and a beta of 1.90. The stock’s 50-day moving average is $5.78 and its two-hundred day moving average is $6.64.

Myriad Genetics (NASDAQ:MYGN) last announced its earnings results on Monday, February 23rd. The company reported $0.04 EPS for the quarter, beating the consensus estimate of ($0.02) by $0.06. The business had revenue of $209.80 million for the quarter, compared to analysts’ expectations of $207.57 million. Myriad Genetics had a negative return on equity of 7.11% and a negative net margin of 48.53%.The firm’s revenue was down .4% on a year-over-year basis. During the same period in the prior year, the business posted $0.03 earnings per share. On average, equities research analysts anticipate that Myriad Genetics will post -0.3 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Myriad Genetics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in MYGN. Millennium Management LLC lifted its stake in shares of Myriad Genetics by 41.1% during the 4th quarter. Millennium Management LLC now owns 6,700,158 shares of the company’s stock valued at $41,206,000 after buying an additional 1,951,831 shares in the last quarter. Jacobs Levy Equity Management Inc. lifted its position in shares of Myriad Genetics by 157.0% during the third quarter. Jacobs Levy Equity Management Inc. now owns 2,442,912 shares of the company’s stock worth $17,662,000 after acquiring an additional 1,492,405 shares in the last quarter. Kent Lake PR LLC bought a new position in shares of Myriad Genetics in the second quarter worth $6,638,000. Federated Hermes Inc. grew its position in shares of Myriad Genetics by 103,916.0% in the second quarter. Federated Hermes Inc. now owns 1,122,333 shares of the company’s stock valued at $5,960,000 after purchasing an additional 1,121,254 shares in the last quarter. Finally, State Street Corp lifted its holdings in Myriad Genetics by 19.9% during the 4th quarter. State Street Corp now owns 5,966,567 shares of the company’s stock worth $36,694,000 after purchasing an additional 990,075 shares in the last quarter. 99.02% of the stock is currently owned by institutional investors.

Key Myriad Genetics News

Here are the key news stories impacting Myriad Genetics this week:

• Positive Sentiment: Q4 earnings and revenue beat consensus — Myriad reported $0.04 EPS (vs. a loss expected) and revenue slightly above forecasts, driving the initial market rally. Read More.
• Positive Sentiment: Q1 outlook points to revenue growth — Management sees Q1 revenue rising roughly 2%–4% year‑over‑year, which supports near‑term top‑line momentum. Read More.
• Neutral Sentiment: Company reiterated FY2026 revenue guidance — Myriad reaffirmed its FY2026 revenue range (~$860M–$880M), signaling management confidence but not an upgrade to guidance. Read More.
• Neutral Sentiment: Earnings call and materials available for detail — The transcript and slide deck provide more color on segment trends, cash flow and the drivers behind the beat; investors should review management’s commentary on reimbursement and product mix. Read More.
• Negative Sentiment: Gross margin pressure and weaker mental-health test sales — Coverage highlights a slip in gross margin and a decline in mental-health business, which temper the positive headline beat. Read More.
• Negative Sentiment: Analyst skepticism: BofA reiterates Sell — Bank of America kept a Sell rating and $4 price target citing execution and reimbursement risks, a counterweight to today’s rally. Read More.
• Negative Sentiment: Mixed third‑party earnings reports/interpretations — Some outlets reported weaker operating results and data discrepancies that could fuel volatility until filings/call details are fully parsed. Read More.

About Myriad Genetics

Myriad Genetics (NASDAQ: MYGN) is a molecular diagnostics company that develops and commercializes genetic tests designed to assess an individual’s risk for various hereditary conditions and to guide personalized treatment decisions. The company’s core business centers on predictive medicine, with a focus on hereditary cancer risk assessment through its flagship BRACAnalysis® test for BRCA1 and BRCA2 gene mutations. In addition to oncology, Myriad offers tests in women’s health, neurology and pharmacogenomics to support more informed clinical decision-making.

Among its product offerings are the myRisk® Hereditary Cancer test, which screens for mutations across multiple cancer-related genes, and Prequel®, a non-invasive prenatal test for assessing fetal chromosomal abnormalities.